Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Phase 3 EMN24 IsKia trial shows Isa-KRd significantly improved NGS-MRD negativity 10-6 (68% vs 48% for KRd; OR 2.36, P=0.0004) in NDMM TE pts w/ good safety (G3-4 non-heme AEs, treatment stops, deaths due to AEs similar).”
Title: Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial
Authors: Francesca Gay, Wilfried Roeloffzen, Meletios A. Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Roberto Mina, Albert Oriol, Eirini Katodritou, Ka Lung Wu, Paula Rodríguez Otero, Roman Hájek, Elisabetta Antonioli, Mark van Duin, Mattia D’Agostino, Joaquín Martínez-López, Elena M. van Leeuwen-Segarceanu, Elena Zamagni, Niels W. C. J. van de Donk, Katja C. Weisel, Luděk Pour, Jakub Radocha, Angelo Belotti, Fredrik Schjesvold, Joan Bladé, Hermann Einsele, Pieter Sonneveld, Mario Boccadoro, Annemiek Broijl
You can read the Full Article in Nature Medicine.
You can find other articles featuring Robert Orlowski on OncoDaily.
